AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11757002 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted system with grafting (graft group)
Number of subjects: 31
Study 11757002 — intervention group
Group type: COMPARATOR
Intervention: Empirical repositioning method (control group)
Number of subjects: 31
Study 30126085 — intervention group
Group type: EXPERIMENTAL
Intervention: RespiraSense™
Number of subjects: 17
Study 30126085 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 17
Study 30126085 — intervention group
Group type: COMPARATOR
Intervention: Manual counts
Number of subjects: 17
Study 30126085 — intervention group
Group type: EXPERIMENTAL
Intervention: RespiraSense™ vs Capnography
Number of subjects: 17
Study 26449197 — intervention group
Group type: EXPERIMENTAL
Intervention: Community optometrists making lesion reactivation decisions
Number of subjects: 96
Study 24384646 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen-based hormone therapy (HT)
Number of subjects: 729
Study 24384646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study 22648840 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding with enteral nutrition preparation
Number of subjects: 60
Study 22648840 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative care protocol
Number of subjects: 60
Study 20395537 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin ER 7.5 mg
Number of subjects: 72
Study 20395537 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin ER 15 mg
Number of subjects: 72
Study 20395537 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 4 mg
Number of subjects: 72
Study 18713926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg followed by 42 microg x kg(‐1) x h(‐1) (ketamine-1 group)
Number of subjects: 3
Study 18713926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg followed by 83 microg x kg(‐1) x h(‐1) (ketamine-2 group)
Number of subjects: 3
Study 18713926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketamine)
Number of subjects: 3
Study 15957569 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS feedback group (bupropion‐SR 150 mg)
Number of subjects: 97
Study 15957569 — intervention group
Group type: COMPARATOR
Intervention: No-feedback group (placebo)
Number of subjects: 97
Study 12391068 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg twice daily for 5 doses)
Number of subjects: 9
Study 11099326 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia (rV)‐CEA followed by three avipox‐CEA vaccinations
Number of subjects: 18
Study 11099326 — intervention group
Group type: COMPARATOR
Intervention: avipox‐CEA (three times) followed by one rV‐CEA vaccination
Number of subjects: 18
Study 11099326 — intervention group
Group type: EXPERIMENTAL
Intervention: local granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and low‐dose interleukin (IL)‐2 with subsequent vaccinations
Number of subjects: 18
Study 9065257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-6791
Number of subjects: 0
Study 9065257 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study 1642024 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (0.3 mg/kg)
Number of subjects: 11
Study 1642024 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (1 mg/kg)
Number of subjects: 11
Study 1642024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6365599 — intervention group
Group type: EXPERIMENTAL
Intervention: Loupe (n = 36)
Number of subjects: 72
Study 6365599 — intervention group
Group type: COMPARATOR
Intervention: Microscope (n = 36)
Number of subjects: 72
Study 31498393 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboot Online (8-lesson multidisciplinary pain management program)
Number of subjects: 80
Study 31498393 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 80
Study 27820726 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation (n = 13)
Number of subjects: 27
Study 27820726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 27
Study 27450591 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary medical male circumcision (VMMC)
Number of subjects: 40
Study 25115136 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based multimedia training
Number of subjects: 92
Study 25115136 — intervention group
Group type: COMPARATOR
Intervention: Comparable reading materials
Number of subjects: 92
Study 22466461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 145
Study 20298639 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 reading intervention
Number of subjects: 236
Study 18031482 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood physical abuse
Number of subjects: 21000
Study 18031482 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 21000
Study 18031482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both childhood sexual and physical abuse
Number of subjects: 21000
Study 15968551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral femoral cutaneous nerve (LFCN) block
Number of subjects: 40
Study 15968551 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve (FN) block
Number of subjects: 40
Study 12161042 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones (Promensil)
Number of subjects: 30
Study 12161042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10519337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine-prilocaine cream (EMLA)
Number of subjects: 34
Study 10519337 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine gel (Ametop)
Number of subjects: 34
Study 10519337 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 34
Study 7864266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 39
Study 7864266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8443031 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin tablets (250 micrograms)
Number of subjects: 12
Study 8443031 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid filled digoxin capsules (100 micrograms)
Number of subjects: 12
Study 8443031 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental enteric-coated capsule (100 micrograms)
Number of subjects: 12
Study 8443031 — intervention group
Group type: COMPARATOR
Intervention: Intravenous control
Number of subjects: 12
Study 2428462 — intervention group
Group type: EXPERIMENTAL
Intervention: BCVPP-Bleo (BCNU, cyclophosphamide, vinblastine, procarbazine, prednisone, and bleomycin)
Number of subjects: 212
Study 2428462 — intervention group
Group type: COMPARATOR
Intervention: Alternating regimen (same drugs alternating in monthly cycles with doxorubicin, dacarbazine, and bleomycin)
Number of subjects: 212
Study 2428462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 212
Study 29477574 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV screening, education, and care coordination (active linkage intervention)
Number of subjects: 0
Study 29477574 — intervention group
Group type: COMPARATOR
Intervention: HCV screening and education (control)
Number of subjects: 0
Study 27769563 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerex (novel porous titanium construct)
Number of subjects: 61
Study 27769563 — intervention group
Group type: COMPARATOR
Intervention: PPS (porous plasma sprayed tibial component)
Number of subjects: 61
Study 25954758 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic SHB (60% HA/40% bTCP) with aPRF
Number of subjects: 82
Study 25954758 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic SHB (100% bTCP) with aPRF
Number of subjects: 82
Study 25954758 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic SHB (60% HA/40% bTCP) without aPRF
Number of subjects: 82
Study 25954758 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic SHB (100% bTCP) without aPRF
Number of subjects: 82
Study 23318149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal H1N1 vaccine
Number of subjects: 363
Study 23318149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 21307169 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2502
Study 21307169 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2502
Study 21307169 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) in symptomatic patients
Number of subjects: 2502
Study 21307169 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) in symptomatic patients
Number of subjects: 2502
Study 21307169 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) in asymptomatic patients
Number of subjects: 2502
Study 21307169 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) in asymptomatic patients
Number of subjects: 2502
Study 19185140 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass
Number of subjects: 349
Study 19185140 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting with cardiopulmonary bypass
Number of subjects: 349
Study 16999610 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind access and totally tubeless percutaneous nephrolithotomy (PCNL)
Number of subjects: 70
Study 16999610 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic transurethral ureterolithotripsy
Number of subjects: 70
Study 15298243 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile Soft‐Seal Cuff (Permeable: P)
Number of subjects: 40
Study 15298243 — intervention group
Group type: COMPARATOR
Intervention: Portex Soft‐Seal Cuff (Resistant: R)
Number of subjects: 40
Study 15298243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (P and R)
Number of subjects: 40
Study 11093564 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant mothers' anticipated workload increase
Number of subjects: 149
Study 11093564 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant fathers' anticipated workload increase
Number of subjects: 149
Study 11093564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum work hours planned by women
Number of subjects: 149
Study 11093564 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with partner's contribution to household work
Number of subjects: 149
Study 11093564 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruency in partners' perceptions of household work sharing
Number of subjects: 149
Study 9520161 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zidovudine treatment
Number of subjects: 70
Study 9520161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7997375 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor scintigraphy (123I-IBZM)
Number of subjects: 26
Study 7997375 — intervention group
Group type: COMPARATOR
Intervention: Cerebral perfusion (99m-Tc-HMPAO)
Number of subjects: 26
Study 7997375 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntington's chorea patients
Number of subjects: 26
Study 2895483 — intervention group
Group type: COMPARATOR
Intervention: Remoxipride 150‐600 mg/day
Number of subjects: 8
Study 2895483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29131129 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 30
Study 29131129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27036379 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC)
Number of subjects: 0
Study 27036379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27036379 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab (TCZ)
Number of subjects: 0
Study 25539805 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative-mechanism TNF-inhibitor (TNFi) or abatacept
Number of subjects: 0
Study 25539805 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0
Study 22061867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 101
Study 22061867 — intervention group
Group type: COMPARATOR
Intervention: Community treatment by experts
Number of subjects: 101
Study 21092191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1510
Study 21092191 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1510
Study 18707799 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl-aminolevulinate (MAL) cream applied under occlusion for 3 hours, followed by illumination with red light-emitting diode (630 nm, light dose 37 J/cm2)
Number of subjects: 49
Study 18707799 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied under occlusion for 3 hours, followed by illumination with red light-emitting diode (630 nm, light dose 37 J/cm2)
Number of subjects: 49
Study 15975990 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% rapamycin-eluting stent
Number of subjects: 602
Study 15975990 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% rapamycin-eluting stent
Number of subjects: 602
Study 15975990 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% rapamycin-eluting stent
Number of subjects: 602
Study 15975990 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 602
Study 12208437 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 40
Study 12208437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Number of subjects: 40
Study 12208437 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 40
Study 12208437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride and buffered lidocaine
Number of subjects: 40
Study 9717924 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 9717924 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture needle
Number of subjects: 60
Study 2717521 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral ketorolac tromethamine (KT)
Number of subjects: 12
Study 2717521 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intramuscular ketorolac tromethamine (KT)
Number of subjects: 12
Study 1015602 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg
Number of subjects: 3
Study 1015602 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 3
Study 1015602 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.6 mg and Metoclopramide 10 mg in combination
Number of subjects: 3
Study 31740074 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention (home visits and telephone follow-up for 5 months)
Number of subjects: 154
Study 31740074 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 154
Study 31740074 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention
Number of subjects: 154
Study 31740074 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study 31139877 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 1691
Study 31139877 — intervention group
Group type: COMPARATOR
Intervention: CYP inducers (concurrent medication)
Number of subjects: 1691
Study 31139877 — intervention group
Group type: COMPARATOR
Intervention: CYP3A4 inhibitors (co-medications)
Number of subjects: 1691
Study 31139877 — intervention group
Group type: COMPARATOR
Intervention: Gender (female)
Number of subjects: 1691
Study 28121185 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) post-HFM at 60% peak oxygen uptake on a treadmill for 1 h
Number of subjects: 58
Study 28121185 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (CON) post-HFM
Number of subjects: 58
Study 25894440 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention bias modification (4 weeks of computer-based training)
Number of subjects: 0
Study 25894440 — intervention group
Group type: COMPARATOR
Intervention: Placebo attention training (4 weeks)
Number of subjects: 0
Study 23324373 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-formal education with HIV prevention education
Number of subjects: 55
Study 23324373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 23324373 — intervention group
Group type: EXPERIMENTAL
Intervention: Savings education
Number of subjects: 55
Study 21287660 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus stress management psychotherapy (three group sessions and 6-9 individual sessions with booster sessions at 6 and 12 months)
Number of subjects: 114
Study 21287660 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 114
Study 19075192 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily
Number of subjects: 77
Study 19075192 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly
Number of subjects: 77
Study 19075192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Alendronate and Indapamide
Number of subjects: 77
Study 17719934 — intervention group
Group type: EXPERIMENTAL
Intervention: INH-A21 (Veronate)
Number of subjects: 1983
Study 17719934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1983
Study 15179024 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate 2000 mg/day
Number of subjects: 0
Study 15179024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11216976 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral loading dose of propafenone (600 mg)
Number of subjects: 0
Study 9532990 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 822
Study 9532990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 822
Study 7993984 — intervention group
Group type: COMPARATOR
Intervention: Colestipol (10 g)
Number of subjects: 6
Study 7993984 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (8 g)
Number of subjects: 6
Study 3246168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (Rocephin)
Number of subjects: 40
Study 3246168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (Cefobis)
Number of subjects: 40
Study 510196 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 tablets of 800 mg bacampicillin (t.i.d.)
Number of subjects: 66
Study 510196 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 tablets of 800 mg bacampicillin (t.i.d.)
Number of subjects: 66
Study 510196 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 tablets of 800 mg bacampicillin (t.i.d.)
Number of subjects: 66
Study 30572160 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) thrice weekly for 3–5 weeks
Number of subjects: 400
Study 30572160 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine twice weekly for 3–5 weeks
Number of subjects: 400
Study 30572160 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 400
Study 30572160 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 400
Study 27819714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy (n = 15)
Number of subjects: 29
Study 27819714 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 14)
Number of subjects: 29
Study 25575875 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate radiotherapy (21 Gy in 3 fractions over 3 working days within 42 days of the pleural intervention)
Number of subjects: 203
Study 25575875 — intervention group
Group type: COMPARATOR
Intervention: Deferred radiotherapy (21 Gy in 3 fractions over 3 working days given if a PTM develops)
Number of subjects: 203
Study 25575875 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate radiotherapy
Number of subjects: 203
Study 25575875 — intervention group
Group type: COMPARATOR
Intervention: Deferred radiotherapy
Number of subjects: 203
Study 23702567 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 253
Study 23702567 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (> 4 h/night)
Number of subjects: 253
Study 22930136 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (on period)
Number of subjects: 20
Study 22930136 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (off period)
Number of subjects: 20
Study 22930136 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 20
Study 21268294 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (Dialipon, Byocerulin, Glutargin)
Number of subjects: 89
Study 21268294 — intervention group
Group type: EXPERIMENTAL
Intervention: Byocerulin
Number of subjects: 89
Study 21268294 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialipon
Number of subjects: 89
Study 18277743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic toothbrush
Number of subjects: 20
Study 18277743 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 20
Study 16033749 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracycline
Number of subjects: 0
Study 16033749 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin for the surgical patient
Number of subjects: 0
Study 16033749 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin for the surgical patient and all household members
Number of subjects: 0
Study 11894033 — intervention group
Group type: EXPERIMENTAL
Intervention: Early carotid endarterectomy (CEA) performed within 30 days after stroke
Number of subjects: 86
Study 11894033 — intervention group
Group type: COMPARATOR
Intervention: Delayed carotid endarterectomy (CEA) performed more than 30 days after stroke
Number of subjects: 86
Study 9568825 — intervention group
Group type: EXPERIMENTAL
Intervention: 1alpha-hydroxyvitamin D2 (1alphaD2), 10 microg thrice weekly with haemodialysis
Number of subjects: 80
Study 9568825 — intervention group
Group type: EXPERIMENTAL
Intervention: 1alpha-hydroxyvitamin D2 (1alphaD2)
Number of subjects: 80